`______________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`______________________
`
`
`REGENERON PHARMACEUTICALS, INC.,
`Petitioner,
`
`v.
`
`NOVARTIS PHARMA AG,
`NOVARTIS TECHNOLOGY LLC,
`NOVARTIS PHARMACEUTICALS CORPORATION,
`Patent Owner.
`
`________________________
`
`Case IPR2021-00816
`U.S. Patent No. 9,220,631 B2
`________________________
`
`JOINT MOTION TO EXPUNGE
`
`
`
`
`
`
`
`
`
`
`
`Pursuant to the Board’s July 13, 2022 email, Patent Owners Novartis
`
`Pharma AG, Novartis Technology LLC, and Novartis Pharmaceuticals
`
`Corporation (collectively, “Novartis”) and Petitioner Regeneron Pharmaceuticals,
`
`Inc. (“Regeneron”) (Regeneron and Novartis, collectively, “Parties”) respectfully
`
`request that the Board expunge the exhibits listed below:
`
`Ex. 1114
`
`Ex. 1101 Declaration of Dr. Gregory Sawyer – Filed Under Seal
`Ex. 1110 Persson, et. al., Elastic contact mechanics: Percolation of the contact
`area and fluid squeeze-out, Eur. Phys. J. E. (2012)
`Ex. 1112 NOVITC(CH)00137958 – Novartis Confidential Internal
`Memorandum – Filed Under Seal
`Ex. 1113 NOVITC(CH)00143346 – Novartis Confidential Internal
`Memorandum – Filed Under Seal
` NOVITC(CH)00258369 – Novartis Confidential Internal
`Presentation – Filed Under Seal
`Ex. 1116 NOVITC(CH)00195649 – Vetter Confidential Memorandum – Filed
`Under Seal
`Ex. 1117 NOVITC(CH)00145642 – Novartis Confidential Meeting Minutes –
`Filed Under Seal
`Ex. 1118 NOVITC(CH)00144912 – Novartis Confidential Meeting Minutes –
`Filed Under Seal
`Ex. 1119 NOVITC(CH)00205699 – Vetter Confidential Presentation – Filed
`Under Seal
`Ex. 1120 NOVITC(CH)00184035 – Vetter Confidential Memorandum – Filed
`Under Seal
`Ex. 1121 NOVITC(CH)00198709 – Vetter Confidential Presentation – Filed
`Under Seal
`Ex. 1122 NOVITC(CH)00867567 – Vetter Confidential Memorandum – Filed
`Under Seal
`Ex. 1123 NOVITC(CH)00150140 – Vetter Confidential Emails – Filed Under
`Seal
`Ex. 1124 NOVITC(CH)00337493 – Vetter Confidential Presentation –Filed
`Under Seal
`Ex. 1125 NOVITC(CH)00352054 – Vetter Confidential Emails – Filed Under
`Seal
`
`
`
`1
`
`
`
`Ex. 1126 VETTER_00001432 – Vetter Confidential Presentation – Filed Under
`Seal
`Ex. 1127 NOVITC(CH)00170626 – Vetter Confidential Memorandum – Filed
`Under Seal
`Ex. 1128 NOVITC(CH)00170434 – Vetter Confidential Letter – Filed Under
`Seal
`Ex. 1129 REGITC01116474 – DE 20 2012 011 016.0
`Ex. 1130 NOVITC(CH)00170689 – Novartis Confidential Agreement – Filed
`Under Seal
`Ex. 1131 NOVITC(CH)00217299 – Novartis Confidential Presentation – Filed
`Under Seal
`Ex. 1132 NOVITC(CH)00311660 – Novartis Confidential Report – Filed
`Under Seal
`Ex. 1133 NOVITC(CH)00133717 – Novartis Confidential Report – Filed
`Under Seal
`Ex. 1134 NOVITC(CH)03375527 – Novartis Confidential Presentation – Filed
`Under Seal
`Ex. 1135 NOVITC(CH)03530811 – Novartis Confidential Presentation – Filed
`Under Seal
`Ex. 1136 NOVITC(CH)03540210 – Novartis Confidential Presentation – Filed
`Under Seal
`Ex. 1160 Picci ITC Deposition Transcript (12/16/2020) – Filed Under Seal
`Ex. 1163 REGITC00138524 – Requirements on pre-fillable glass syringes
`Ex. 1164 Optical in Situ Micro Tribometer for Analysis of Real Contact Area
`for Contact Mechanics, Adhesion, and Sliding Experiments, B. A.
`Krick, J. R. Vail, B. N. J. Persson, and W. G. Sawyer, Tribology
`Letters 45 (2012) 185-194
`Ex. 1165 Plasmonic Diagnostics for Tribology: In Situ Observations using
`Surface Plasmon Resonance in Combination with Surface-Enhanced
`Raman Spectroscopy, B. A. Krick, D. H. Hahn, and W. G. Sawyer,
`Tribology Letters, 49 (2013) 95-102.
`Ex. 1166 Accessing Inaccessible Interfaces: In Situ Approaches to Materials
`Tribology, W. G. Sawyer & K. J. Wahl, Guest Editors MRS Bulletin
`33 (2008) 1145-1189
`Ex. 1167 VETTER_10013300_EN (Certified Translation) – Vetter
`Confidential Emails – Filed Under Seal
`Ex. 1169 Lorenz, et al., Static or breakloose friction for lubricated contacts:
`the role of surface roughness and dewetting, J. Phys. Condens. Matter
`25 (2013)
`
`
`
`2
`
`
`
`Ex. 1181 “Beovu (brolucizumab injection) now publicly reimbursed in Ontario
`and New Brunswick for the treatment of neovascular (wet) age-
`related macular degeneration,” Yahoo Finanace, December 16, 2021,
`available at https://finance.yahoo.com/news/beovu-brolucizumab-
`injectionnow-publicly-120000109.html?guccounter=1
`Ex. 2208 Declaration of Kimberly Cameron, Ph.D. In Support of Novartis’s
`Motion to Amend [Filed Under Seal]
`Ex. 2210 Curriculum Vitae of Dr. Kimberly Cameron
`Ex. 2211 Curriculum Vitae of Dr. Jeremy Wolfe
`Ex. 2212 Eylea Label 2021
`Ex. 2213 Lucentis Label 2017
`Ex. 2214 Rahul Chaturvedi et al., Real World Trends in Intravitreal Injection
`Practices Among American Retina Specialists, Ophthalmology Retina
`(Aug. 2019), 3(8):656-662
`Ex. 2218 Francesco Cilurzo et al., Injectability Evaluation: An Open Issue,
`AAPS PharmSciTech (June 2011), 12(2):604-9
`Ex. 2222 Summary of EU Product Characteristics, Lucentis PFS (E.U.)
`Ex. 2229 Nitin Rathore et al., Variability in Syringe Components and its Impact
`on Functionality of Delivery Systems, PDA J. Pharm. Sci. Tech.
`(201), 65(5):468-480
`Ex. 2230 European Medicines Agency, ICH Topic Q 5 C, “Quality of
`Biotechnological Products,” CPMP/ICH/138/95 (July 1996)
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`3
`
`
`
`Dated: August 12, 2022
`
`By: /Elizabeth J. Holland/
`Elizabeth J. Holland (Reg. No. 47,657)
`Lead Counsel for Patent Owners
`Allen & Overy LLP
`1221 Avenue of the Americas
`New York, NY 10020
`Phone: + 212 610 6365
`elizabeth.holland@allenovery.com
`
`By: /Anish R. Desai/
`
`Anish R. Desai (Reg. No. 73,760)
`Lead Counsel for Petitioner
`Weil, Gotshal & Manges LLP
`767 Fifth Avenue
`New York, NY 10153
`T: 212-310-8730
`anish.desai@weil.com
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`4
`
`
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
`
`
`The undersigned hereby certifies that on August 12, 2022 the foregoing
`
`JOINT MOTION TO EXPUNGE was served via electronic mail upon the
`
`following:
`
`Elizabeth J. Holland
`Allen & Overy LLP
`221 Avenue of the Americas
`New York, NY 10020
`elizabeth.holland@allenovery.com
`
`Nicholas K. Mitrokostas
`Allen & Overy LLP
`1 Beacon Street
`Boston, MA 02108
`nicholas.mitrokostas@allenovery.com
`
`William G. James
`Allen & Overy LLP
`1101 New York Avenue, N.W
`Washington, D.C 20005
`william.james@allenovery.com
`
`
`
`/Daniela Toribio/ 1
`Daniela Toribio
`IP Paralegal
`Weil, Gotshal & Manges LLP
`2001 M Street, NW, Suite 600
`Washington, D.C. 20036
`T: 202-682-7000
`daniela.toribio@weil.com
`
`
`
`5
`
`